V938
Biological
Merck Sharp & Dohme Corporation
Total Payments
$324,175
Transactions
55
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $313,622 | 41 | 0 |
| 2019 | $10,553 | 14 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $321,900 | 50 | 99.3% |
| Consulting Fee | $2,275 | 5 | 0.7% |
Payments by Type
Research
$321,900
50 transactions
General
$2,275
5 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Protocol Title A Phase 1,1b, Open label Clinical Study of Intratumoral,Intralesional Administration of V938 in Combination with Pembrolizumab MK 3475 in Participants with Advanced,Metastatic or Recurrent Malignancies | Merck Sharp & Dohme Corporation | $321,900 | 0 |
Top Doctors Receiving Payments for V938
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $321,900 | 50 |
| , M.D | Diagnostic Radiology | Kendall Park, NJ | $2,275 | 5 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $324,175
Product Information
- Type Biological
- Total Payments $324,175
- Total Doctors 1
- Transactions 55
About V938
V938 is a biological associated with $324,175 in payments to 1 healthcare providers, recorded across 55 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2019 to 2020. In 2020, $313,622 was paid across 41 transactions to 0 doctors.
The most common payment nature for V938 is "Unspecified" ($321,900, 99.3% of total).
V938 is associated with 1 research study, including "Protocol Title A Phase 1,1b, Open label Clinical Study of Intratumoral,Intralesional Administration of V938 in Combination with Pembrolizumab MK 3475 in Participants with Advanced,Metastatic or Recurrent Malignancies" ($321,900).